Bicara Therapeutics, Inc. (BCAX)
9.71
-0.05
(-0.51%)
USD |
NASDAQ |
Oct 29, 16:00
9.40
-0.31
(-3.19%)
After-Hours: 20:00
Bicara Therapeutics Net Income (Quarterly) : -55.44M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -55.44M |
| March 31, 2026 | -56.21M |
| December 31, 2025 | -37.39M |
| September 30, 2025 | -36.33M |
| June 30, 2025 | -27.39M |
| March 31, 2025 | -36.85M |
| Date | Value |
|---|---|
| December 31, 2024 | -20.96M |
| September 30, 2024 | -17.48M |
| June 30, 2024 | -17.05M |
| March 31, 2024 | -12.51M |
| December 31, 2023 | -12.44M |
| September 30, 2023 | -22.84M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
| Anixa Biosciences, Inc. | -2.625M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 55.44M |
| EPS Diluted (Quarterly) | -0.8161 |
| Enterprise Value | 147.39M |
| Earnings Yield | -31.78% |
| Normalized Earnings Yield | -31.78 |